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Abstract
Aims Sexual dysfunction is common among patients with heart failure (HF)
and considered an important hamper to quality of life. While implantation of
left ventricular assist device (LVAD) may prolong and improve life in advanced
HF, limited data are available on its impact on sexual function. The aim of this
study is to evaluate sexual function in LVAD patients and compare this with
patients after heart transplantation (HTx).
Methods and results Sexual activity and satisfaction of stable patients with
durable LVAD or after HTx were evaluated using a validated questionnaire
and visual analogue scale from 0 to 10. Data were collected from 31 patients
(mean age 59±12years, 87% male), 17 after HTx and 14 with LVAD. Pleasure
or satisfaction with sex was significantly higher in HTx patients (P=0.0005). In
total, 29% LVAD patients and 71% HTx patients reported content with sexual
activity. Recalled satisfaction with sex life pre-operation was comparable
between the groups. During support, satisfaction with sex life using visual ana-
logue scale was 7.6±3.1 for HTx versus 3.9±4.0 for LVAD patients (P=0.017).
In total, 11 LVAD patients (79%) reported specific problems in sexual function
including erectile dysfunction or vaginal dryness (8, 57%); problems with the
LVAD, cable, or batteries (5, 36%); problems with orgasm (4,29%); and other
problems such as fear of injury, feeling depressed, partner issues, self-image,
and pain (1, 7% each).
Conclusion Sexual dysfunction occurs in patients with LVAD support and
may be more prominent than after HTx. Problems limiting sexual function
related to physiological, psychological, and equipment merit consideration
during follow-up.
Keywords Sexual function; Left ventricular assist device; Heart failure; Heart
transplantation
Introduction
Heart failure (HF) is a prevalent clinical syndrome involving functional impair-
ment due to insufficient cardiac function. Sexual function is an important
aspect of general health and one’s quality of life, both in healthy and diseased
persons. Normal sexuality involves the desire, ability, and satisfaction in
performing sex and requires complex social, psychological, and physiological
capacities. The physiological demands in performing sex include the ability
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to perform exercise (about 4 METS)1 and the ability to
sustain erection in men. In women, physiological ability
is less well demonstrable and may manifest with vaginal
lubrication.2 During sexual activity, there is a need for
an increase in heart rate and blood pressure achieving
the peak during orgasm.3–5 To sustain these physiological
demands, multiple systems including cardiac, vascular,
muscle, and nervous must interplay. The physiologic and
social conditions required to maintain normal sexual func-
tion make it a useful sentinel that may be used by the at-
tending health professional to assess general morbidity or
sufficient health.
Because many of the capacities necessary to maintain
sexuality function abnormally in HF patients, it is not sur-
prising that these patients suffer impaired sexual func-
tion.6,7 Negative effects on sexual function have also
been reported with other cardiac conditions and were as-
sociated with anxiety, fear of fatal cardiac event, and lack
of awareness of acceptable activities post-cardiac inci-
dents.8,9 In addition to the risk factors, co-morbidities,
and psychosocial burden that affect the sexual function
of HF patients, treatments have also been associated with
an impact on the quality of life and in particular the sex-
ual function of patients with HF. Although different thera-
peutic interventions may be very effective in improving
HF symptoms and longevity, their impact on sexual as-
pects of life might differ. Heart transplantation (HTx) is
regarded as the optimal treatment for advanced HF pa-
tients; however, in a number of studies, the majority of
HTx patients continued to suffer from sexual dysfunc-
tion.10–12 Implantation of left ventricular assist device
(LVAD) to stage D HF patients is known to prolong and
improve the quality of life.13–15 Even though sexuality is
an element of one’s quality of life,6 there is a lack of data
on the effect of LVAD implantation on the sexual function
of patients with advanced HF. We therefore set out to
evaluate the sexual function of patients with advanced
HF after treatment with LVAD with comparisons with pa-
tients after HTx.
Methods
This is a cross-sectional study including HF patients in
stable medical condition after implantation of a durable
LVAD or after HTx.
Sample
All eligible consecutive patients attending the designated
LVAD and HTx clinics at the HF unit, Rabin Medical Cen-
ter, from November 2012 to July 2013 were approached.
Patients who were hospitalized in the previous month
and/or those who declared not to have a sexual partner
were excluded. Participants who consented were handed
the study questionnaire and independently interviewed
by one of the study medical staff. The protocol of the
study was approved by the institutional ethics committee.
Measurement
Participating patients were asked to complete a question-
naire consisting of four main sections: (1) general infor-
mation, (2) functional ability, (3) medications, and (4)
sexual function. The general information section included
the demographic characteristics of the patient and identi-
fied the patient as part of the LVAD or HTx groups. The
functional ability section was aimed to assess the effort
ability of patients on the basis of the New York Heart As-
sociation (NYHA) classification. The medications section
was completed by the physician or the nurse and included
data on the type and dose of the following medications:
beta blocker, angiotensin-converting enzyme inhibitor or
angiotensin receptor blocker, diuretic, alpha blocker,
phosphodiasterase 5 inhibitor (PDE5i), nitrate, and aldo-
sterone inhibitor. For information on sexual function, a
validated sexual function questionnaire6 was used with
modifications to include appreciated change in sexual
function perceived by the patient to occur since his/her
operation. The questionnaire was translated to Hebrew
and back-translated to English and checked to ensure
consistency. This part included 13 questions regarding
current status and comparing the sexual life of the pa-
tient before operation with the current status. Patients
were asked to grade problems with the spouse, interest
in sexual activity, pleasure or satisfaction with sex,
problems with frequency of sexual activity, and distur-
bance to sexual performance on a scale of 1 to 4. To
describe the change in sexual function as recollected
compared with before surgery, answering possibilities
were1 significant improvement,2 minor improvement,3
no change, or4 deterioration. Satisfaction with sexual
life was rated on a visual analogue scale from 0 to 10
(0 for low, 10 for full satisfaction). Patients first filled
the questionnaire privately and subsequently had the
opportunity to discuss the questions with a clinic nurse
or physician.
Statistical analysis
Continuous data with normal distributions were pre-
sented using mean and standard deviation. Non-normally
distributed variables were presented using median and
first and third quartiles. Categorical data were presented
with frequencies and percentages. Two-sided Wilcoxon
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signed rank test was used for comparisons of continuous
data and Fisher’s exact test for discrete variables;
P<0.05 was considered statistically significant.
Results
Sample characteristics
We approached 36 patients. Two patients supported with
a LVAD and three HTx patients reported not to have a
sexual partner and thus were excluded from the study.
All other 31 patients participated in the study including
14 with LVAD and 17 HTx patients. Two patients after
HTx who were previously bridged with LVAD were consid-
ered in the HTx group. The sample consisted of 27 (87%)
men and 4 women, with a mean age of 59 (SD 12) years.
Among patients with LVAD, 11 were supported with
Heartmate II (Thoratec, Pleasanton, CA) and 3 with
HVAD (Heartware, Framingham, MA). Baseline character-
istics, medications, and functional parameters are shown
in Table 1. The study evaluation was performed later after
the operation in the HTx compared with the LVAD group.
Table 1 Patient characteristics, medications and functional status
All (n=31) LVAD (n=14) HTx (n=17) P
Age (years) 59±12 64± 6 54±14 0.121
Male 27 (87%) 12 (86%) 15 (88%) 1.000
Diabetes mellitus 15 (48%) 6 (43%) 9 (53%) 0.722
Hypertension 15 (48%) 10 (71%) 5 (29%) 0.032*
Ischemic aetiology 23 (77%) 12 (92%) 11 (65%) 0.104
Smoking 0 (0%) 0 (0%) 0 (0%) 1.000
Time from operation months, median (IQR) 14 (6;68) 6 (4;14) 63 (16;111) 0.0001*
Medications:
Beta blockers 21 (68%) 12 (86%) 9 (53%) 0.068
ACE-I or ARB 21 (68%) 12 (86%) 9 (53%) 0.068
Loop diuretic 17 (55%) 12 (86%) 5 (29%) 0.003*
Alpha blocker 4 (13%) 2 (14%) 2 (12%) 1.000
Phosphodiasterase 5 inhibitor 8 (26%) 8 (57%) 0 (0%) 0.0004*
Aldactone antagonist 8 (26%) 8 (57%) 0 (0%) 0.0004*
Functional:
NYHA class> II 9 (29%) 5 (36%) 4 (23%) 0.693
Dizziness 5 (16%) 2 (14%) 3 (18%) 1.000
Unemployed 26 (84%) 14 (100%) 12 (70%) 0.048*
Patient characteristics for all patients and separately for patients in the LVAD and HTx groups as well as comparisons between the groups
are shown. LVAD, left ventricular assist device; HTx, heart transplantation; ACE-I, angiotensin converting enzyme; ARB, angiotensin recep-
tor blocker; NYHA, New York Heart Association.
*Statistically significant (P< 0.05).
Table 2 Sexuality for patients with left ventricular assist device compared with heart transplantation patients at the time of ques-
tionnaire and the change in sexuality compared with pre-operative self-recall
Variable All (n=31) LVAD (n=14) HTx (n=17) P
Problems with the spouse
At time of questionnaire 1.2± 0.5 1.1±0.3 1.3±0.7 0.375
Change since operation 2.5±0.9 2.5±0.9 2.5±0.9 0.891
Interest in sexual activity
At time of questionnaire 2.0± 1.0 2.2±1.0 1.8±0.9 0.231
Change since operation 2.8±1.0 2.8±1.1 2.7±1.0 0.672
Problems with frequency of sexual activity
At time of questionnaire 2.1± 1.2 2.6±1.3 1.7±1.0 0.059
Change since operation 2.6±1.1 2.6±1.1 2.5±1.1 0.770
Pleasure or satisfaction with sex
At time of questionnaire 2.0± 1.2 2.7±1.1 1.3±0.9 0.0005*
Change since operation 2.5±1.1 2.8±1.0 2.2±1.1 0.161
Disturbance to sexual performance
At time of questionnaire 2.0± 1.3 2.8±1.4 1.5±0.9 0.011*
Change since operation 2.4±1.0 2.6±0.9 2.3±1.0 0.349
Answers to sex life related questions for all, patients with LVAD, and HTx patients using a 1 to 4 scale where 1 is better and 4 is worse.
Possible answers to describe the change in sexual function were1 significant improvement,2 minor improvement,3 no change, and4
deterioration. Comparisons were made between LVAD and HTx groups.
LVAD, left ventricular assist device; HTx, heart transplantation.
*Statistically significant (P< 0.05).
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There was a trend for older age among LVAD patients with
mean age difference of 10 years, not statistically different
(P=0.121). Patients with LVAD had more history of
hypertension and were more often treated with loop
diuretics and with aldosterone antagonist. Eight patients
from the LVAD group were treated with PDE5i for
pulmonary hypertension, typically with sildenafil 20mg
TID. About a third of the patients in the LVAD and a
quarter of those in the HTx groups reported significant
effort limitations (NYHA class> II), and the majority
reported no current employment.
Sexual activity
Sexual activity variables are shown in Table 2. HTx patients
reported better pleasurewith sexual activity comparedwith
the LVAD patients. In total, two LVAD patients (14%) had
full satisfaction, five (36%) had mild disturbance, two
(14%) had significant disturbance, and five (36%) patients
reported no pleasure or satisfaction with sex. In the HTx
group, the majority (14, 82%) of the patients reported hav-
ing full pleasure or satisfaction. Most patients ranked the
change since operation as minor or non-significant.
Other differences between the groups shown in Table 2
were found with identifying a problem in the frequency of
performing sex and with disturbance to sexual perfor-
mance. Distribution of problem with performing sexual
activity among patients with LVAD and HTx is shown in
Figure 1. Twenty-nine per cent in the LVAD group reported
no problem with sexual activity compared with 71% in
the post-HTx group.
The results of the visual analogue scale for general sat-
isfaction with sex life are shown in Table 3. The recalled
satisfaction with sex life before the operation for both
groups was not significantly different. During follow-up,
the satisfaction with sex life in the post-HTx group was
better than for the LVAD group. The changes in satisfac-
tion for both groups are shown in Figure 2. Whereas gen-
eral satisfaction is shown to improve in patients with HTx,
there is a more mixed picture among those with LVAD,
with an overall trend for less content.
Among the patients with LVAD, 11 patients (79%)
reported on specific reasons that may contribute to
problems in sexual function and performance. Listed
causes were the following: erectile dysfunction or dryness
(8, 57%); problems with the LVAD device, cable, or batte-
ries (5, 36%); problems with orgasm (4, 29%); fear of in-
jury (1, 7%); feeling depressed (1, 7%); partner issues (1,
7%); problem of self-image (1, 7%); and pain (1, 7%).
Among the patients after HTx, 11 (65%) reported specific
problems including erectile dysfunction or dryness (4,
23%), feeling depressed (3, 18%), partner issues (3,
18%), weakness (2, 12%), and fear of injury (1, 6%).
Discussion
In this study, we investigated sexual function of patients
on chronic continuous flow LVAD support and compared
A.
B.
Figure 1 Problems with performing sexual activity among pa-
tients with left ventricular assist device and after heart
transplantation.
Table 3 General satisfaction with sex life (current and compared with pre-operative)
Variable
All LVAD HTx
P
(n=31) (n=14) (n=17)
Satisfaction with sex life before surgery (0–10 scale) 5.5± 3.8 4.7±4.3 6.1±3.3 0.336
Satisfaction with sex life current (0–10 scale) 5.9± 3.9 3.9±4.0 7.6±3.1 0.017*
Change in satisfaction with sex life pre-operative to current 0.4± 3.7 0.8±1.8 1.4±4.6 0.050*
Results of a 0–10 visual analogue scale regarding general satisfaction with sex life (0 for low, 10 for full satisfaction) among all patients,
those with LVAD, and HTx patients with comparison between the LVAD and HTx groups. Patients were asked on the current satisfaction as
well as the recalled satisfaction before the operation.
LVAD, left ventricular assist device; HTx, heart transplantation.
*Statistically significant (P< 0.05).
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this with the sexual function of patients after HTx. Despite
satisfactory effort ability, we found significant limitations
to sexuality in both groups that seemed more prominent
among patients supported with an LVAD. These limita-
tions were attributed to specific causes in the majority
of patients.
This is a novel study that provides insights regarding
the sexual function of HF patients supported with an
LVAD. While patients with advanced HF treated with
LVAD enjoy multiple benefits including decrease in mor-
bidity and mortality, sexual health among these patients
has been scarcely investigated. Interviewing nine patients
with LVADs, one report suggested improved sexual function
attributed to the LVAD support.16 A survey conducted
among 301 patients with durable continuous flow LVAD
using the Changes in Sexual Function Questionnaire-14
was recently published. Only 59 patients (20%) responded
to this questionnaire, and among those, sexual dysfunction
was identified in the majority (71% in men and 79% in
women).17 While responder bias may confound the inter-
pretation, these results suggest post-LVAD sexual
limitations similar to the findings in the current study.
In this study, patients reported a mean value of 5.9
(on a scale from 0 to 10) in scoring the satisfaction with
their current sex life, and they looked back on their sex
life before the operation scoring a 5.5. This is higher
compared with a HF population without LVAD or HTx,6
where patients scored 4.5 for their current sex life. In
that study, patients rated their current satisfaction with
sexuality lower than before their disease and lower than
healthy community controls. All patients were less satis-
fied with their current sexuality than before their HF.
Surprisingly in our study, while HTx patients
experienced an overall increase in satisfaction with sex
life, LVAD patients reported an overall decrease.
When directly inquired regarding sexual function dur-
ing the interview, all patients were forthcoming to dis-
cuss the subject, and specific contributing factors have
been identified in the majority. Performance dysfunction
(erectile dysfunction or vaginal dryness) was the most
prevalent. Multiple factors might contribute to erectile
dysfunction among patients supported with LVAD includ-
ing low systolic blood pressure, previous co-morbidity
(such as diabetes mellitus or peripheral vascular), and in-
sufficient cardiac output. Erectile dysfunction could also
be attributed in part to endothelial dysfunction that has
been suggested in patients on continuous flow de-
vices.18,19 Therefore, it is possible that factors
contributing to sexual dysfunction with HF are not
completely reversed during the LVAD support. As there
B.
A.
Figure 2 Satisfaction with sex life among patients with left ventricular assist device and after heart transplantation.
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is little knowledge about sexual function after heart
transplant and LVAD, some extrapolations can be de-
duced from reports on other solid organ transplant. With
renal replacement therapy, it is interesting that erectile
function is impaired in both patients undergoing hemodi-
alysis as well as after kidney transplant compared with
healthy controls20 (although somewhat better after
transplant21). After liver transplant, sexual function im-
proves, but not to the level of healthy controls,22 also im-
plying that complete recovery of sexuality after chronic
organ dysfunction is rare.
Another contributor to sexual dysfunction was associ-
ated with LVAD machinery. Quality of life in patients liv-
ing with older first-generation LVADs has been shown to
be significantly lower than patients 3months post-
HTx.23 The currently used newer devices are smaller, ligh-
ter, and compatible with near-normal lifestyle. However,
the abdominal power cable exit and dependence on exter-
nal batteries may still cause problems with intimacy and
sexual activity. Modifications of driveline exit site such
as the post-auricular or lower chest may have advantages
over the traditional abdominal site for infection preven-
tion as well as be more suited for intimacy. Certainly,
the futuristic wireless LVAD may improve quality of life in-
cluding sex life.
A third type of contributing factor is more psychosocial
in nature and includes fear, depression, altered self-
image, and problems with the partner. Similar problems
were reported in patients with HF without LVAD or
HTx.6 These may further aggravate the ‘physiological’ dis-
turbances and vice versa to form a mutually reinforcing
triad of depressive symptoms, cardiovascular disease,
and erectile dysfunction.24 Specific counselling, both
medical and psychological, may be helpful in alleviating
these issues.
This study is the first to compare LVAD and HTx pa-
tients and strengthens previous observations that sexual
dysfunction might persist under LVAD support. Patients
in our experience were forthcoming and thankful for ad-
dressing sexual issues during the interview, and impor-
tant potentially reversible issues were identified. By
raising the awareness of the medical teams taking care
of LVAD-supported patients, we hope patient’s care may
be improved in this important aspect of well-being. Future
studies will examine the effectiveness of such interven-
tional efforts.
Limitations and strengths
The study is limited in sample size and therefore should
be considered accordingly as hypothesis generating. The
cross-sectional design incurred limitations in the ability
to compare changes in sex life, and the use of recalled sat-
isfaction may be influenced by the current status. There is
no control group of HF patients on medical therapy, al-
though comparison was performed with published infor-
mation on such a group using a similar questionnaire.
We did not perform a psychological evaluation of the pa-
tients, and performing this may have added to the under-
standing of causes of sexual dysfunction. The population
at our centre is diverse and includes Ashkenazi, non-
Ashkenazi Jews, and Arabs; therefore, there may be social
differences in this population. However the diversity of
the population may be considered a strength as well.
The comparison of patients on LVAD support with patients
after HTx carries obvious limitations. Specifically, the dif-
ferent times after the operation may have selected health-
ier patients in the HTx group. On the other hand, such a
comparison can also be considered a strength, as both
groups have (had) severe HF and an intense medical
intervention, changing the course of their disease and
daily life. The study setting carries a possible strength as
HTx and LVAD patients are treated in the same clinic by
similar health professionals, and the clinical setting
achieved the degree of intimacy allowing patients to ex-
pose problems in sexuality.
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